WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection

Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"

PR NewswireDec 12 16:30

The tenth batch of Pharmaceutical centralized procurement in the mainland is about to begin bidding, with 62 types of Pharmaceuticals included in the national procurement.

The national Pharmaceutical procurement declaration information public conference will be held today (12th) in Shanghai, signaling the upcoming opening of bids for the tenth national Pharmaceutical concentrated procurement. This national procurement includes 62 types of Pharmaceuticals. Since the pilot for concentrated Pharmaceutical procurement launched in 2018 in four direct-controlled municipalities and seven sub-provincial cities, the process has gradually normalized. In recent years, it has generally occurred twice a year, while the tenth batch of procurement is the only national procurement for 2024. This national procurement includes 62 types of Pharmaceuticals, covering various disease areas such as cardiovascular and cerebrovascular, digestive, tumors, and metabolism, with more than half being injections sold through Hospital channels. The procurement cycle for each variety is determined by the selection results.

AASTOCKSDec 12 10:32

WUXI BIO (2269.HK): Global Biomedical financing recovery drives valuation and performance restoration.

We anticipate that the Biosecurity Bill is likely to fail in legislation, which would be bullish for the company to continuously achieve performance growth in a relatively stable operating environment. With the recovery of global Biomedical financing, the company valuation and performance recovery look bullish.

Silver InternationalDec 12 08:42 · Researches

Express News | CITIC Construction Investment: Optimistic about investment opportunities in the pharmaceutical industry in 2025, focusing on new volume and industry integration opportunities

BreakingsDec 12 07:38

Express News | The tenth batch of national centralized procurement will open bids in Shanghai tomorrow: involving 62 varieties, with strict measures to prevent companies from colluding and manipulating the bidding.

BreakingsDec 11 17:13

John Lee Ka-chiu: The long-term goal is to establish the Hong Kong Drug Administration to jointly leverage the advantages of clinical trials with the Mainland.

During an interview with RTHK, Chief Executive John Lee Ka-chiu stated that the long-term goal of the authorities is to have its own drug regulatory agency that can approve medicines and medical devices. To achieve this goal, it is necessary to establish an office to prepare, including the need to join international organizations and strengthen clinical research. John Lee mentioned that Hong Kong and the mainland can jointly leverage advantages in clinical trials, including utilizing mainland data, such as patient databases from the 1.4 billion population or nearly 80 million people in the Greater Bay Area. When top-tier clinical trials can be conducted, pharmaceutical companies can be attracted to Hong Kong, increasing the city's competitiveness and business opportunities.

AASTOCKSDec 11 09:34